From TLX yesterday
The study utilises copper-64 (64Cu) which isdetectable by Positron Emission Tomography (PET) as a surrogate for actinium-225 (225Ac),enabling a successful proof-of-targeting study as well as predictive dosimetry calculations for futurestudies with 225Ac.
Interesting use (validation?) of Cu64 in imaging from the competition?
- Forums
- ASX - By Stock
- CU6
- Research/Valuation
Research/Valuation, page-410
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$5.18 |
Change
0.150(2.98%) |
Mkt cap ! $1.619B |
Open | High | Low | Value | Volume |
$5.05 | $5.22 | $5.04 | $3.900M | 758.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 10671 | $5.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.18 | 8737 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 5001 | 5.180 |
17 | 8905 | 5.170 |
16 | 27204 | 5.160 |
3 | 2165 | 5.150 |
4 | 10570 | 5.140 |
Price($) | Vol. | No. |
---|---|---|
5.190 | 9797 | 24 |
5.200 | 21175 | 13 |
5.210 | 13816 | 10 |
5.220 | 11828 | 7 |
5.230 | 5446 | 6 |
Last trade - 14.47pm 03/07/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online